DRAK2 Antibody (C-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP7221b
Background:
DRAK2 is a novel serine/threonine kinase that induces apoptosis via catalytic activity. DRAKs present high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases. DRAK2 is located in nucleus, and the messenger RNA is ubiquitously expressed in human tissues.
Other Names:
Serine/threonine-protein kinase 17B, DAP kinase-related apoptosis-inducing protein kinase 2, STK17B, DRAK2
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7221b was selected from the C-term region of human DRAK2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: STK17B
Gene ID: 9262
Primary Accession: O94768
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
DRAK2 is a novel serine/threonine kinase that induces apoptosis via catalytic activity. DRAKs present high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases. DRAK2 is located in nucleus, and the messenger RNA is ubiquitously expressed in human tissues.
Other Names:
Serine/threonine-protein kinase 17B, DAP kinase-related apoptosis-inducing protein kinase 2, STK17B, DRAK2
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7221b was selected from the C-term region of human DRAK2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: STK17B
Gene ID: 9262
Primary Accession: O94768
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review